212 related articles for article (PubMed ID: 10999772)
1. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R
Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytotoxicity of S16020-2, a new olivacine derivative.
Léonce S; Perez V; Casabianca-Pignede MR; Anstett M; Bisagni E; Pierré A; Atassi G
Invest New Drugs; 1996; 14(2):169-80. PubMed ID: 8913838
[TBL] [Abstract][Full Text] [Related]
3. The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis.
Maggiorella L; Frascogna V; Poullain MG; Berlion M; Lucas C; Razy SD; Eschwege F; Bourhis J
Clin Cancer Res; 2001 Jul; 7(7):2091-5. PubMed ID: 11448928
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
5. Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain.
Le Mée S; Chaminade F; Delaporte C; Markovits J; Saucier JM; Jacquemin-Sablon A
Mol Pharmacol; 2000 Oct; 58(4):709-18. PubMed ID: 10999940
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
7. S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition.
Le Mée S; Pierré A; Markovits J; Atassi G; Jacquemin-Sablon A; Saucier JM
Mol Pharmacol; 1998 Feb; 53(2):213-20. PubMed ID: 9463478
[TBL] [Abstract][Full Text] [Related]
8. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
10. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines.
Pierré A; Léonce S; Pérez V; Atassi G
Cancer Chemother Pharmacol; 1998; 42(6):454-60. PubMed ID: 9788571
[TBL] [Abstract][Full Text] [Related]
11. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
[TBL] [Abstract][Full Text] [Related]
13. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
[TBL] [Abstract][Full Text] [Related]
14. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
[TBL] [Abstract][Full Text] [Related]
15. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
16. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure, and cytostatic properties of new olivacine derivatives.
Jasztold-Howorko R; Croisy A; Carrez D; Jaroszewicz I; Nasulewicz A; Pełczyńska M; Opolski A
Arch Pharm (Weinheim); 2004 Nov; 337(11):599-604. PubMed ID: 15543533
[TBL] [Abstract][Full Text] [Related]
18. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
Anyanwutaku IO; Guo X; Chen HX; Ji Z; Lee KH; Cheng YC
Mol Pharmacol; 1996 Apr; 49(4):721-6. PubMed ID: 8609902
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
20. Comparative cytotoxicities of a series of ellipticine and olivacine derivatives on multidrug resistant cells of human and murine origins.
Chevallier-Multon MC; Jacquemin-Sablon A; Besselièvre R; Husson HP; Le Pecq JB
Anticancer Drug Des; 1990 Nov; 5(4):319-35. PubMed ID: 1981310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
